Sanofi Gets Green Light on Blockbuster Heart Treatment
July 8th 2009Sanofi-Aventis is banking that its highly anticipated atrial fibrillation/flutter treatment Multaq will be a huge success. The path to approval has been ridden with a failed trial and a very long review process, but for Sanofi, the wait has been worth it.
Expression systems royalties battle
July 1st 2009Biopharmaceutical companies generally try to avoid paying royalties on novel technologies, including novel expression systems, in part because of the inability to predict revenue flow after a product is commercialized. But even when a new expression system could significantly reduce cost, many remain hesitant. Despite this, adopting new technologies continues to be fundamental to improving product quality and cost.
ASCO Roundup: Winners, Losers, and Also Rans
June 3rd 2009Due to pharma's voluntary moratorium on doling out totefuls of freebies and all the lattes you can swallow, thousands of docs, researchers, and reporters had only their sleep-deprived selves to carry from data dump to data dump at this week?s American Society of Clinical Oncology (ASCO) annual confab in Orlando, Florida.